Innovent gains access to universal CAR-T platform
Suzhou cancer drug maker Innovent Biologics signed up with Roche to access the Swiss pharma giant’s universal CAR-T platform to discover and develop T-cell therapies and bispecific antibodies, signaling a greater emphasis on developing cellular therapies in its pipeline development.
"Innovent first entered the cellular therapy space a few years ago, and with this partnership with Roche we are taking a much bolder step forward,” Innovent founder, chairman, and CEO Michael Yu said in a statement.
The dollar amount of the deal was undisclosed but the deal includes an upfront payment, as well as development and commercial milestone payments and royalties for therapies developed with the platform. Roche can still offer the same platform to other drug manufacturers.
Roche also retains the option to license-in Innovent’s products for development and commercialization for ex-China markets, which could potentially net the Chinese pharma upwards of $2 billion if all of the products are successfully commercialized.
"Innovent first entered the cellular therapy space a few years ago, and with this partnership with Roche we are taking a much bolder step forward,” Innovent founder, chairman, and CEO Michael Yu said in a statement.
The dollar amount of the deal was undisclosed but the deal includes an upfront payment, as well as development and commercial milestone payments and royalties for therapies developed with the platform. Roche can still offer the same platform to other drug manufacturers.
Roche also retains the option to license-in Innovent’s products for development and commercialization for ex-China markets, which could potentially net the Chinese pharma upwards of $2 billion if all of the products are successfully commercialized.
No hay comentarios:
Publicar un comentario